Keith Regnante

Keith Regnante

Plus aucun poste en cours

Fortune : 98 495 $ au 31/07/2026

56 ans
Health Technology
Consumer Services

Profil

Keith C.
Regnante
worked at Biogen, Inc. from 1999 to 2013, serving as Senior Director-Corporate Finance from 2011 to 2013.
From 2013 to 2014, worked at ARIAD Pharmaceuticals, Inc. as Head-Research & Development Finance.
Between 2014 and 2016, held the position of Vice President-Finance at Shire Pharmaceuticals, Inc. From 2016 to 2020, was Chief Financial & Accounting Officer at Wave Life Sciences Ltd. From 2020 to 2026, served as Chief Financial Officer at Keros Therapeutics, Inc. Education includes an undergraduate degree from Tufts University and an MBA from MIT Sloan School of Management.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
31/03/2026 9 781 ( 0,05 % ) 98 495 $ 31/07/2026

Anciens postes connus de Keith Regnante

SociétésPosteFin
KEROS THERAPEUTICS, INC. Directeur Financier/CFO 03/08/2026
WAVE LIFE SCIENCES LTD. Directeur Financier/CFO 09/01/2020
Corporate Officer/Principal 01/08/2016
ARIAD PHARMACEUTICALS, INC. Corporate Officer/Principal 01/02/2014
BIOGEN INC. Public Communications Contact 01/08/2013
Voir l'expérience en détail de Keith Regnante

Formation de Keith Regnante

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

82

Relations au 1er degré

7

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées7

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Consumer Services

Health Technology

  1. Bourse
  2. Insiders
  3. Keith Regnante
🔇